IMMX · Immix Biopharma, Inc.
$8.44
-0.25 (-2.88%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$459.23M
Shares
54.41M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | CFO | $1,352,854 |
| Ilya Rachman | CEO | $1,352,854 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | CFO | $1,267,158 |
| Ilya Rachman | CEO | $1,267,158 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | CFO | $1,129,881 |
| Ilya Rachman | CEO | $1,129,881 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | CFO | $2,356,145 |
| Ilya Rachman | CEO | $2,356,145 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gabriel Morris | CFO | $462,091 |
| Ilya Rachman | CEO | $396,731 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ilya Rachman | CEO | — |
| Gabriel Morris | CFO | — |